Pulmonary arterial hypertension: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PI3K 0
• NLRP3 0
• STAT3 0
• AKT 0
• HIF-1 0
• GLP-1 2
• mTOR 0
• CD19 2
• IL-6 0
• SGLT2 0
• CXCR4 0
• SIRT1 0
• ACE2 0
• AMPK 0
• HDAC 0
• HMGB1 0
• HSP90 0
• NRF2 0
• TNF 0
• YAP 0
• ABL1 0
• BCMA 2
• CTNNB1 0
• FAK 0
• PPAR 0
• RUNX1 0
• TLR4 0
• VEGF 0
• VHL 1
• ALK 1
• AR 0
• DPP-4 0
• ERK 0
• GIP 1
• GPX4 0
• HER3 0
• IGF1R 0
• JAK 0
• MAPK 0
• MDM2 0
• METTL3 0
• NOTCH3 0
• PARP 0
• PIK3CA 0
• PTEN 0
• STING 0
• TP53 0

24 of 847 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Design and development of explainable DL/ML model for medical image analysis with high accuracy and reliability (MED-XAI)

  Universidade Nova de Lisboa· Lisboa, Portugal· EU contribution €207,183· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Pulmonary Hypertension in COPD : from Observation to Emerging Novel therapeutic Insights and eXploration (PHOENIX)

  Universitat Zurich· Zurich, Switzerland· EU contribution €292,119· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Mending sex differences: Unravelling the female predominance in pulmonary hypertension (FEMALE-PH)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €1,499,999· until Feb 2028

3 of 3 running projects, newest first. Listed amounts together: €2.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT04816604· Gossamer Bio USA, Inc.· Updated 5 Nov 2026

  “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect study interpretation or the overall benefit-risk.”Registry text, quoted unchanged. Source

• Withdrawn

  A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia

  NCT06327373· Duke University· Updated 3 Sept 2026

  “Funding not obtained”Registry text, quoted unchanged. Source

• Terminated

  Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

  NCT05140525· Dr Sudarshan Rajagopal· Updated 3 Sept 2026

  “Sponsor Requested”Registry text, quoted unchanged. Source

• Terminated

  A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

  NCT01065454· Bayer· Updated 20 Aug 2026

  “The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at the time the study was terminated.”Registry text, quoted unchanged. Source

• Withdrawn

  Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

  NCT07221513· Salubris Biotherapeutics Inc· Updated 15 May 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Suspended

  Exercise Training to Improve Cardiopulmonary Hemodynamics in Heart Failure Patients

  NCT04909008· Mayo Clinic· Updated 4 May 2026

  “Lack of recruitment”Registry text, quoted unchanged. Source

• Suspended

  Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  NCT07181382· GB002, Inc.· Updated 19 Mar 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH

  NCT05618093· University of California, Los Angeles· Updated 3 Feb 2026

  “Study device no longer available”Registry text, quoted unchanged. Source

• Withdrawn

  Pulmonary Vascular Hemodynamics Before and After Mitral Valve Procedures

  NCT04947384· University of Alabama at Birmingham· Updated 27 Jan 2026

  “PI moved to a different institution. Low enrollment rate.”Registry text, quoted unchanged. Source

• Terminated

  Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

  NCT05764265· Novartis Pharmaceuticals· Updated 27 Jan 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  2024-513613-12-00· Novartis Pharma AG· Source

• Effects of Inhaled Nitric Oxide on Sublingual Microcirculation in Patients With Right Ventricular Dysfunction After Cardiac Surgery

  NCT07918976· Southeast University, China· Source

• Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions

  NCT07915882· Michael Incze· Source

• A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)

  NCT07600723· Merck Sharp & Dohme LLC· Source

• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Actelion· Source

• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

  NCT04175600· Actelion· Source

• A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea

  NCT07890285· Janssen Korea, Ltd., Korea· Source

• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

  NCT03492177· Actelion· Source

• A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

  NCT05179876· Actelion· Source

• Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

  NCT05587712· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 2
• Gene Expression Profiling 21
• Sequence Analysis, RNA 1
• Exome Sequencing 5
• Proteomics 10
• Metabolomics 11
• Immunohistochemistry 1
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 15
• Machine Learning 15
• Deep Learning 2
• Cohort Studies 18
• Genome-Wide Association Study 7

• Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension.

  Circ Heart Fail, Sept 2026

• Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension.

  JCI Insight, May 2026

• Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

  Int J Mol Sci, Apr 2026

• Right ventricular-centered metabolomics: A promising tool for phenotyping pulmonary arterial hypertension.

  Clin Chim Acta, Apr 2026

• Harnessing metabolomics and proteomics in a clinical trial for pulmonary arterial hypertension: insights from post-hoc analysis of the REHAB-PH trial.

  EBioMedicine, Mar 2026

• Systemic sclerosis-associated pulmonary arterial hypertension and pulmonary fibrosis: exploring biomarker discriminators with advanced omics in a Caucasian cohort.

  Front Immunol, Feb 2026

• Unveiling the protective mechanisms of Pipa Qingfei Decoction in pulmonary arterial hypertension: Insights from network pharmacology, metabolomics and Mendelian randomization.

  J Ethnopharmacol, Jan 2026

• Plasma non-targeted metabolomics unveils the metabolic signatures of trans-right ventricle in pulmonary arterial hypertension associated with atrial septal defect.

  Clin Chim Acta, Jan 2026

• Metabolomic signature of right ventricular-pulmonary arterial coupling differentiates hemodynamic response to imatinib therapy in pulmonary arterial hypertension.

  J Heart Lung Transplant, Dec 2025

• Influence of atorvastatin on metabolic pattern of rats with pulmonary hypertension.

  Aging (Albany NY), Apr 2021

See which targets of this disease your abstract mentions, and go to the people working on them.